By analyzing the survival-related genes of ACC patients, we found that the expression of cyclin-dependent kinase-1 (CDK1) was significantly correlated with the survival of ACC patients and is likely to be a therapeutic target for ACC. This evidence concerns the gene CDK1 and adrenal cortex carcinoma.